Premium
Visualization drugs for vitreoretinal surgery
Author(s) -
TADAYONI R
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2008.5212.x
Subject(s) - vitreoretinal surgery , medicine , visualization , optometry , ophthalmology , computer science , vitrectomy , artificial intelligence , visual acuity
Purpose To discuss data on the potential or real toxicity of intraocular visualization drugs, based on animal and human studies. Methods The course will be based on last experimental and clinical data available in the literature or from our studies. Results There is a larger choice of visualizations drugs with a clear benefit of helping the surgeon. Each of them has its own advantages and risks. The decision to use or not these drugs should also take into account the goal for which they may be used and the expected benefit from it. Conclusion Visualizations drugs, as most drugs, may represent risks that have to be weighed up against awaited benefits.